SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: patlawche11 who wrote (47502)11/28/2018 10:10:00 AM
From: patlawche1110 Recommendations

Recommended By
alwayshope
Dietman
dorightbythem
drtom1234
erippetoe

and 5 more members

   of 63285
 
Phase III Ascent Trial for TNBC updated last week (Nov. 21, 2018).

What's notable is the number of new study locations open and now recruiting outside of the US, specifically Canada - 2 new locations, France - 9 new locations, Germany - 5 new locations, Spain - 1 new location, and the UK - 8 new locations.

I seem to recall Michael Pehl saying awhile back that once IMMU132 is approved in the US, they expect recruitment to significantly drop off in the US and that recruitment outside of the US will provide much of the additional patients required to complete the study. Hopefully a good sign!

clinicaltrials.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News